Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)
Study Details
Study Description
Brief Summary
This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in very young children. The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds).
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Detailed Description
Young children age 3-5.5 years will be studied. The study includes treatment with different doses of methylphenidate and placebo; all children will receive active medication during the study. Prior to treatment, each child will receive a thorough psychiatric evaluation and each guardian will complete a 10-week workshop (2 hours/week). Throughout the study, parents and teachers will complete forms that report on the child's behavior and possible side effects. Participants will be monitored by regular visits with a study physician. Most participants will be involved in the study for up to 16 months to ensure optimal evaluation, dosing, and monitoring
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Boys and girls who are:
-
Between the ages of 3-5.5 years
-
Qualified as having ADHD by our diagnostic evaluations and clinical staff
-
Otherwise generally healthy
-
Willing, and have parents that are willing, to attend all visits required by the study
-
Enrolled in some type of day-program: day care, preschool, nursery school, kindergarten, for at least 2 half days/week
-
In classrooms with teachers that are willing to participate by completing rating scale
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of California, Irvine | Irvine | California | United States | |
2 | University of California, Los Angeles | Los Angeles | California | United States | |
3 | Johns Hopkins University | Baltimore | Maryland | United States | |
4 | New York State Psychiatric Institute | New York | New York | United States | |
5 | New York University School of Medicine | New York | New York | United States | |
6 | Duke University Medical Center | Durham | North Carolina | United States |
Sponsors and Collaborators
- New York State Psychiatric Institute
- National Institute of Mental Health (NIMH)
Investigators
- Study Chair: Laurence Greenhill, M.D.,
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
- Barkley RA. The effects of methylphenidate on the interactions of preschool ADHD children with their mothers. J Am Acad Child Adolesc Psychiatry. 1988 May;27(3):336-41.
- Conners CK: Controlled trial of methylphenidate in preschool children with minimal brain dysfunction. Int J Ment Health (4):61-74, 1975.
- Handen BL, Feldman HM, Lurier A, Murray PJ. Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD. J Am Acad Child Adolesc Psychiatry. 1999 Jul;38(7):805-12.
- Mayes SD, Crites DL, Bixler EO, Humphrey FJ 2nd, Mattison RE. Methylphenidate and ADHD: influence of age, IQ and neurodevelopmental status. Dev Med Child Neurol. 1994 Dec;36(12):1099-107.
- Musten LM, Firestone P, Pisterman S, Bennett S, Mercer J. Effects of methylphenidate on preschool children with ADHD: cognitive and behavioral functions. J Am Acad Child Adolesc Psychiatry. 1997 Oct;36(10):1407-15.
- Schleifer M, Weiss G, Cohen N, Elman M, Cvejic H, Kruger E. Hyperactivity in preschoolers and the effect of methylphenidate. Am J Orthopsychiatry. 1975 Jan;45(1):38-50. doi: 10.1111/j.1939-0025.1975.tb01164.x.
- #3761
- U01MH060903
- U01MH060642
- U01MH060943
- U01MH060848
- U01MH060900
- U01MH060833
- DSIR CT-M2